Quick Summary
- Rapid CSU Relief with Rhapsido®: New Phase 3 pooled analysis from the REMIX-1 and -2 trials shows that Rhapsido (remibrutinib) provides significant improvement in itch and hive severity in patients with chronic spontaneous urticaria as early as Week 1 of treatment.
- Proven Longevity for Cosentyx®: Long-term data reinforce Cosentyx (secukinumab) as a durable solution, maintaining efficacy and safety for up to 4 years in hidradenitis suppurativa (HS) and 5 years in psoriasis and psoriatic arthritis.
- Competitive Edge & Disease Prevention: Novartis showcased data comparing Cosentyx favorably against bimekizumab for flare prevention in HS, while also presenting evidence that early Cosentyx use may help prevent the progression of psoriatic arthritis in psoriasis patients.
Novartis immunology data at AAD 2026 highlights a significant shift toward rapid symptom intervention and sustained long-term management for patients battling complex skin conditions. At this year’s American Academy of Dermatology (AAD) Annual Meeting in Denver, Novartis is presenting a robust portfolio of over 20 abstracts, reinforcing its leadership in the immunology space with standout data for Rhapsido® (remibrutinib) and Cosentyx® (secukinumab).
The data drop focuses on two primary fronts: the rapid onset of symptom relief in chronic spontaneous urticaria (CSU) and the enduring efficacy of treatments for hidradenitis suppurativa (HS) and psoriasis.
Rhapsido: Speed is the Story in CSU
For patients living with the unpredictable “itch and hive” cycle of chronic spontaneous urticaria, waiting weeks for relief isn’t just an inconvenience; it’s a quality-of-life crisis. Novartis is set to present a pooled analysis from the REMIX-1 and -2 Phase 3 studies, which reveals that Rhapsido (remibrutinib) provides significant symptom control as early as Week 1.
The presentation will highlight dramatic changes in Daily Itch Severity and Hives Severity scores. By demonstrating such a fast-acting profile, Novartis is positioning Rhapsido as a potential gold standard for patients who need their lives back immediately.
- Key Highlight: The REASSERT study, a multi-country prospective study, will also be featured, providing a real-world look at how remibrutinib performs across global populations.
Read More: Novartis Achieves Phase III Remibrutinib Trial Primary Endpoint in Chronic Inducible Urticaria
Cosentyx: The Marathon Runner of Immunology
While Rhapsido handles the “sprint,” Cosentyx is doubling down on its reputation for long-term reliability. Novartis is presenting four-year efficacy data from the SUNSHINE and SUNRISE trials in HS, alongside five-year data for psoriasis and psoriatic arthritis.
Perhaps most notably for clinicians, Novartis is bringing an indirect comparison to the floor. A matched adjusted indirect comparison (MAIC) analysis will pit Cosentyx against bimekizumab regarding safety and flare prevention in HS. In a field that is becoming increasingly crowded with biologics, Novartis is leaning into its “extensive body of evidence” to prove that continuous, long-term use is both safe and effective.
These presentations demonstrate the strength of our immunology portfolio and our ongoing efforts to help patients manage chronic diseases that significantly impact their lives and overall well-being.
Angelika Jahreis
Expanding the Horizon: Adolescents and Prevention
The data isn’t just for adults. Novartis is also utilizing model-informed drug development to design dosing regimens for adolescents (ages 12+) suffering from moderate to severe HS—a population often underserved in clinical trials.
Furthermore, the company is exploring the “preventative” side of immunology. Data from the ERASURE, FIXTURE, and SCULPTURE studies suggest that Cosentyx may play a role in preventing the progression to psoriatic arthritis in patients currently dealing with moderate to severe psoriasis.
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
Major Presentations to Watch at AAD 2026
| Molecule | Disease State | Focus | Date/Time (MT) |
| Rhapsido® | CSU | Week 1 Symptom Improvement | March 27, 3:15 pm |
| Cosentyx® | HS | vs. Bimekizumab (Indirect Comparison) | March 27, 1:45 pm |
| Cosentyx® | Psoriatic Arthritis | Prevention in Psoriasis Patients | March 28, 11:45 am |
| Cosentyx® | HS | 4-Year Long-term Efficacy | March 27 (e-Poster) |
